Skip to main content
. 2020 May 28;3(2):71–84. doi: 10.1093/pcmedi/pbaa017

Table 4.

The major COVID-19 vaccines entering clinical trials worldwide.

Sponsor Candidate vaccine Registration ID ETC
Henan Provincial Center for Disease Control and Prevention Inactivated vaccine ChiCTR2000031809 10 November 2021
Henan Provincial Center for Disease Control and Prevention Inactivated vaccine ChiCTR2000032459 28 November 2021
Sinovac Biotech Co., Ltd Inactivated vaccine NCT04352608 13 December 2020
Shenzhen Geno-Immune Medical Institute Lentiviral vector vaccine NCT04299724, NCT04276896 31 July 2023
Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China Adenovirus vector vaccine NCT04341389 31 January 2021
CanSino Biologics Inc. Adenovirus vector vaccine (Adenovirus Type 5 Vector) NCT04313127 30 December 2020
Inovio Pharmaceuticals DNA vaccine (INO-4800) NCT04336410 November 2020
Symvivo Corporation DNA vaccine NCT04334980 31 August 2021
National Institute of Allergy and Infectious Diseases (NIAID) mRNA vaccine (mRNA-1273) NCT04283461 1 June 2021
Biontech SE 4 RNA vaccines NCT04368728 27 January 2023
Novavax Recombinant Spike Protein Nanoparticle Vaccine NCT04368988 31 July 2021

ECT: Estimated time of completion.